Reteplase

Description

Reteplase is a thrombolytic agent used in the treatment of acute myocardial infarction to dissolve the blood clots by binding to the proteins involved in the formation of the clots and restores the blood circulation to the blocked blood vessels. This medicine is not recommended for use in patients below 18 years of age.

Side effects

Major & minor side effects for Reteplase

  • Bleeding at injection site
  • Blood in urine
  • Stomach pain
  • Pale skin
  • Unusual tiredness or weakness
  • Blurred vision
  • Dizziness
  • Fast heartbeat
  • Confusion

Uses of Reteplase

What is it prescribed for?

  • Acute myocardial infarction
Read More
Concerns

Commonly asked questions

  • Onset of action
    The effect of this medicine can be observed within 30-90 minutes of administration of the dose.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to reteplase or any other inactive ingredients present in the formulation.

Bleeding

This medicine is not recommended for use in patients who have a current intracranial hemorrhage, subarachnoid hemorrhage, active internal bleeding, or underwent any intracranial or intraspinal surgery or serious head trauma within the past 3 months.

Severe uncontrolled hypertension

This medicine is not recommended for use in patients with severe uncontrolled hypertension due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
General warnings

Severe Bleeding

This medicine may increase the risk of bleeding, therefore should be used with caution in patients with any bleeding disorder. Inform the doctor if you have any gastrointestinal diseases, previous history of trauma, surgery, stroke or uncontrolled hypertension . Close monitoring is necessary and therapy should be discontinued in case of any signs of internal bleeding.

Use in children

This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Use in Elderly

This medicine should be used with extreme caution in the elderly, as the risk of adverse effects were significantly high.

Severe Liver/Kidney Disease

This medicine should be used with caution in patients with severe liver/kidney diseases due to the increased risk of adverse effects. Regular monitoring of liver/kidney function tests is necessary for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Missed Dose

Since this medicine is administered in a clinical setting under the supervision of a healthcare professional the chances of missing a dose is rare.

Overdose

Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Dabigatran

Etodolac

Citalopram

Duloxetine

Fluvoxamine

Apixaban

Abciximab

Disease interactions

Cardiovascular disorders

This medicine is not recommended for use in patients with cardiovascular diseases like portal hypertension, severe uncontrolled hypertension. Caution is advised to use in patients with arrhythmias due to the increased risk of worsening of the patient's condition. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually to administered under the supervision of a doctor in a clinical setup with regular monitoring of blood clotting time and other related parameters. It should not be injected into the muscles. Your doctor may ask you to undergo certain tests to determine the safety of use of this medicine.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by dissolving the blood clots and restoring the blood flow to the blocked blood vessels.
Legal Status

Approved

Approved

Unknown

Approved

Classification

Category

Thrombolytics

Schedule

Schedule H

[Internet]. 2018 [cited 6 December 2018]. Available from:

https://www.glowm.com/resources/glowm/cd/pages/drugs/qr013.html

[Internet]. Ebs.tga.gov.au. 2018 [cited 6 December 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01717-3&d=201812061016933

Reteplase - DrugBank [Internet]. Drugbank.ca. 2018 [cited 6 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB00015

[Internet]. Ema.europa.eu. 2018 [cited 6 December 2018]. Available from:

https://www.ema.europa.eu/documents/product-information/rapilysin-epar-product-information_en.pdf

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 23 Aug 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.